Compare DARE & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DARE | GRF |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | 24 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 41.0M |
| IPO Year | 2014 | N/A |
| Metric | DARE | GRF |
|---|---|---|
| Price | $2.36 | $10.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 769.5K | 2.9K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.16 |
| Revenue | ★ $2,807,885.00 | N/A |
| Revenue This Year | $2,115.12 | N/A |
| Revenue Next Year | $122.62 | N/A |
| P/E Ratio | ★ N/A | $8.72 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $9.50 |
| 52 Week High | $9.19 | $11.85 |
| Indicator | DARE | GRF |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 46.62 |
| Support Level | $1.79 | $9.96 |
| Resistance Level | $2.54 | $10.04 |
| Average True Range (ATR) | 0.35 | 0.21 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 22.28 | 31.65 |
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.